Rituximab therapy in adults with steroid-dependent nephrotic syndrome

作者：Zhong, Hongzhen; Li, Hong-Yan; Zhou, Tianbiao^*; Weng, Wenjuan

来源：Archives of Medical Science, 2023, 19(3): 577-585.

DOI：10.5114/aoms.2019.88404

• steroid-dependent nephrotic syndrome
• rituximab
• efficacy
• safety

Introduction: Patients with steroid-dependent nephrotic syndrome (SDNS) suffer frequent relapse with adverse effects caused by long-term predniso-lone treatment. Recently, the chimeric monoclonal antibody against the pro-tein CD20 (rituximab - RTX) was observed to be efficacious and safe in the treatment of patients with SDNS. We summarized the scientific literature to evaluate RTX therapy in the clinical management of SDNS.Material and methods: PubMed, EMBASE, and Cochrane Library databases were investigated from interception to 2019-6-6, without language limita-tion. The analysis was restricted to adults & GE; 19 years of age. Data were ad-ministered and analyzed through the Review manager 5.3 software.Results: After RTX treatment, relapse times, prednisolone dose, and protein-uria decreased, whereas serum albumin was increased. The clinical param-eters blood pressure and total cholesterol diminished also, whereas bone mineral density was improved. Overall, RTX ameliorated the adverse effects of prednisolone. Moreover, the Th1/Th2 ratio was changed except for the CD19 and CD20 cell counts. Additionally, most of the adverse effects of RTX were mild and well tolerated.Conclusions: In the studies that we considered, we concluded that RTX treatment was effective and safe in the therapy of patients with SDNS. Nevertheless, more randomized controlled trials are required to explore the mechanism of RTX action and verify its efficacy.

• 单位
  汕头大学; 南方医科大学